Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ribometrix Inc. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, COLEMAN, BRENDA LIBBY, who is the busiest examiner for the company. The prosecution is localized within 1 distinct art unit, showing a concentrated effort in this specific technological field. This arrangement suggests that the company is focusing its current intellectual property strategy on a single, specific innovation within the biotech sector.
The busiest_examiner_pending count of 1 for COLEMAN, BRENDA LIBBY matches the total volume of pending office actions for the portfolio. This indicates that Ribometrix Inc. is currently managing a single point of contact at the patent office for its Biotechnology & Pharmaceuticals interests. The prosecution profile is streamlined, with all current activity concentrated under one examiner. For the practitioner, this means the outcome of the company's current patent efforts depends entirely on the perspective and requirements of this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18508102 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF | COLEMAN, BRENDA LIBBY | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18508102 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | — | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRibometrix Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brenda Libby Coleman has the most, with 1 of Ribometrix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
